Pharming Group N.V.

Pharming Group N.V. (PHAR) shows no detected cyber incidents or red-flag 8-K filings in our 90-day ingestion window, suggesting near-term operational stability. However, a clean recent period does not rule out longer-term structural risks—dilution from financing rounds, equity issuance patterns, or emerging AI-driven signals may warrant deeper scrutiny. The full $49 Report extends the lookback to 12 months, layers in dilution risk scoring and financing history, and surfaces early warning indicators that short windows can miss. That analysis provides the context needed to assess true shareholder risk beyond the absence of acute events.